Assessment of Safety and Preliminary Clinical Efficacy With BAT6005 in Advanced Malignant Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This research design for center, increasing openness, dose and dose extension phase I
clinical trials, research the main evaluation BAT6005 injection single drug in patients with
advanced malignant solid tumors in the safety, tolerability and PK characteristics, to
explore the maximum tolerated dose and preliminary antitumor efficacy, provide the basis for
subsequent clinical trials recommended dose.
Part I: single drug dose escalation study. Part TWO: dose extension study.